title: Effect of charcoal hemoperfusion on clearance of cibenzoline succinate (cifenline) poisoning.
abstract: BACKGROUND
  Management of cibenzoline succinate (cifenline) poisoning by symptomatic treatment is recommended because it has been reported cibenzoline succinate is not effectively removed by hemodialysis. The use of charcoal hemoperfusion for patients with cibenzoline succinate poisoning has not been reported previously.
  
  
  METHODS
  An 80-year-old woman with permanent right ventricular pacing was admitted to our hospital with general fatigue and clouding of consciousness. She had been receiving cibenzoline succinate for 1 month. The patient was clearly in shock on admission. Electrocardiogram showed a prolonged QRS and QTc interval and pacing failure. Hemodynamic failure, electrocardiographic abnormalities including pacing failure, and liver and renal dysfunction were compatible with cibenzoline succinate poisoning. Symptomatic treatment was provided. On day 4, charcoal hemoperfusion was initiated because of the development of hypoglycemia accompanied by liver and renal dysfunction. After charcoal hemoperfusion, the hypoglycemia, liver and renal dysfunction, prolonged QRS and QTc interval, and pacing threshold resolved. She was discharged on digoxin. We present a case of cibenzoline succinate poisoning treated with charcoal hemoperfusion which resulted in a rapid reduction of cibenzoline plasma concentrations with a significant clinical improvement.
authors.affiliation: Department of Emergency and Critical Care Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan. aoyama@med.Kitasato-u.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Aoyama
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Matsuyama
authors.forename: T
authors.initials: T
authors.lastname: Aizaki
authors.forename: T
authors.initials: T
authors.lastname: Izumi
authors.forename: R
authors.initials: R
authors.lastname: Kondo
authors.forename: Y
authors.initials: Y
authors.lastname: Kamijo
authors.forename: K
authors.initials: K
authors.lastname: Soma
authors.forename: T
authors.initials: T
authors.lastname: Ohwada
mesh_terms: D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000506:poisoning*; D002606:Charcoal / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D007093:Imidazoles / Q000506:poisoning*; D007674:Kidney Diseases / Q000139:chemically induced
chemical_list: D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; D002606:Charcoal; C032151:cifenline